Company Overview - Baiyang Pharmaceutical Co., Ltd. is located in Qingdao, Shandong Province, established on March 8, 2005, and listed on June 30, 2021 [1] - The company provides comprehensive commercialization solutions for pharmaceutical product manufacturers, including brand operation, wholesale distribution, and retail, with a focus on marketing solutions for branded pharmaceutical manufacturers [1] Financial Performance - As of June 30, 2025, Baiyang Pharmaceutical achieved a revenue of 3.751 billion yuan, representing a year-on-year growth of 4.36%, while the net profit attributable to shareholders decreased by 55.75% to 163 million yuan [2] - The company has distributed a total of 1.551 billion yuan in dividends since its A-share listing, with 1.201 billion yuan distributed over the past three years [3] Stock Performance - On September 12, Baiyang Pharmaceutical's stock price decreased by 2.01%, trading at 30.72 yuan per share, with a market capitalization of 16.147 billion yuan [1] - The stock has increased by 31.01% year-to-date, with a 13.11% rise over the last five trading days, 17.34% over the last 20 days, and 55.70% over the last 60 days [1] Shareholder Information - As of June 30, 2025, the number of shareholders increased by 15% to 18,800, with an average of 27,926 circulating shares per shareholder, a decrease of 13.05% [2] - Among the top ten circulating shareholders, ICBC Frontier Medical Stock A (001717) ranked as the eighth largest, holding 2.6816 million shares, a decrease of 3.4767 million shares from the previous period [3] Market Position - Baiyang Pharmaceutical operates within the pharmaceutical and biological industry, specifically in the pharmaceutical commercial and distribution sector, and is associated with concepts such as online marketing, high dividends, and financing [2]
百洋医药跌2.01%，成交额7745.37万元，主力资金净流出1243.94万元